vs
TopBuild Corp（BLD）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
TopBuild Corp的季度营收约是Revvity的1.9倍（$1.5B vs $772.1M），Revvity净利率更高（12.7% vs 7.0%，领先5.7%），TopBuild Corp同比增速更快（13.2% vs 5.9%），Revvity自由现金流更多（$161.8M vs $159.4M），过去两年Revvity的营收复合增速更高（9.0% vs 7.8%）
HashiCorp是总部位于美国加利福尼亚州旧金山的软件企业，2012年由米切尔·桥本与阿蒙·达德加创立，采用免费增值商业模式，为开发、运维及安全从业人员提供云基础设施配置、防护、运行与连接相关的工具及产品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BLD vs RVTY — 直观对比
营收规模更大
BLD
是对方的1.9倍
$772.1M
营收增速更快
BLD
高出7.3%
5.9%
净利率更高
RVTY
高出5.7%
7.0%
自由现金流更多
RVTY
多$2.4M
$159.4M
两年增速更快
RVTY
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $772.1M |
| 净利润 | $104.5M | $98.4M |
| 毛利率 | 27.2% | — |
| 营业利润率 | 12.1% | 14.5% |
| 净利率 | 7.0% | 12.7% |
| 营收同比 | 13.2% | 5.9% |
| 净利润同比 | -30.6% | 3.9% |
| 每股收益（稀释后） | $3.69 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLDRVTY
| Q4 25 | $1.5B | $772.1M | ||
| Q3 25 | $1.4B | $698.9M | ||
| Q2 25 | $1.3B | $720.3M | ||
| Q1 25 | $1.2B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.4B | $684.0M | ||
| Q2 24 | $1.4B | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
净利润BLDRVTY
| Q4 25 | $104.5M | $98.4M | ||
| Q3 25 | $142.2M | $46.7M | ||
| Q2 25 | $151.6M | $53.9M | ||
| Q1 25 | $123.4M | $42.2M | ||
| Q4 24 | $150.5M | $94.6M | ||
| Q3 24 | $169.0M | $94.4M | ||
| Q2 24 | $150.7M | $55.4M | ||
| Q1 24 | $152.4M | $26.0M |
毛利率BLDRVTY
| Q4 25 | 27.2% | — | ||
| Q3 25 | 30.1% | 53.6% | ||
| Q2 25 | 30.4% | 54.5% | ||
| Q1 25 | 28.5% | 56.5% | ||
| Q4 24 | 29.9% | — | ||
| Q3 24 | 30.7% | 56.3% | ||
| Q2 24 | 31.0% | 55.7% | ||
| Q1 24 | 30.3% | 54.6% |
营业利润率BLDRVTY
| Q4 25 | 12.1% | 14.5% | ||
| Q3 25 | 15.4% | 11.7% | ||
| Q2 25 | 16.9% | 12.6% | ||
| Q1 25 | 14.4% | 10.9% | ||
| Q4 24 | 16.6% | 16.3% | ||
| Q3 24 | 17.8% | 14.3% | ||
| Q2 24 | 15.4% | 12.4% | ||
| Q1 24 | 16.8% | 6.8% |
净利率BLDRVTY
| Q4 25 | 7.0% | 12.7% | ||
| Q3 25 | 10.2% | 6.7% | ||
| Q2 25 | 11.7% | 7.5% | ||
| Q1 25 | 10.0% | 6.4% | ||
| Q4 24 | 11.5% | 13.0% | ||
| Q3 24 | 12.3% | 13.8% | ||
| Q2 24 | 11.0% | 8.0% | ||
| Q1 24 | 11.9% | 4.0% |
每股收益（稀释后）BLDRVTY
| Q4 25 | $3.69 | $0.86 | ||
| Q3 25 | $5.04 | $0.40 | ||
| Q2 25 | $5.32 | $0.46 | ||
| Q1 25 | $4.23 | $0.35 | ||
| Q4 24 | $5.07 | $0.77 | ||
| Q3 24 | $5.65 | $0.77 | ||
| Q2 24 | $4.78 | $0.45 | ||
| Q1 24 | $4.79 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $184.7M | $919.9M |
| 总债务越低越好 | $2.8B | — |
| 股东权益账面价值 | $2.3B | $7.3B |
| 总资产 | $6.6B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.23× | — |
8季度趋势，按日历期对齐
现金及短期投资BLDRVTY
| Q4 25 | $184.7M | $919.9M | ||
| Q3 25 | $1.1B | $931.4M | ||
| Q2 25 | $842.5M | $991.8M | ||
| Q1 25 | $308.8M | $1.1B | ||
| Q4 24 | $400.3M | $1.2B | ||
| Q3 24 | $257.3M | $1.2B | ||
| Q2 24 | $463.2M | $2.0B | ||
| Q1 24 | $968.8M | $1.7B |
总债务BLDRVTY
| Q4 25 | $2.8B | — | ||
| Q3 25 | $2.9B | — | ||
| Q2 25 | $1.9B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
股东权益BLDRVTY
| Q4 25 | $2.3B | $7.3B | ||
| Q3 25 | $2.2B | $7.4B | ||
| Q2 25 | $2.1B | $7.6B | ||
| Q1 25 | $2.1B | $7.6B | ||
| Q4 24 | $2.2B | $7.7B | ||
| Q3 24 | $2.1B | $7.9B | ||
| Q2 24 | $2.4B | $7.9B | ||
| Q1 24 | $2.7B | $7.8B |
总资产BLDRVTY
| Q4 25 | $6.6B | $12.2B | ||
| Q3 25 | $6.4B | $12.1B | ||
| Q2 25 | $5.1B | $12.4B | ||
| Q1 25 | $4.6B | $12.4B | ||
| Q4 24 | $4.7B | $12.4B | ||
| Q3 24 | $4.7B | $12.8B | ||
| Q2 24 | $4.9B | $13.4B | ||
| Q1 24 | $5.3B | $13.4B |
负债/权益比BLDRVTY
| Q4 25 | 1.23× | — | ||
| Q3 25 | 1.29× | — | ||
| Q2 25 | 0.88× | — | ||
| Q1 25 | 0.65× | — | ||
| Q4 24 | 0.62× | — | ||
| Q3 24 | 0.66× | — | ||
| Q2 24 | 0.59× | — | ||
| Q1 24 | 0.52× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $176.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $159.4M | $161.8M |
| 自由现金流率自由现金流/营收 | 10.7% | 21.0% |
| 资本支出强度资本支出/营收 | 1.2% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.69× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $696.9M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BLDRVTY
| Q4 25 | $176.7M | $182.0M | ||
| Q3 25 | $233.3M | $138.5M | ||
| Q2 25 | $193.7M | $134.3M | ||
| Q1 25 | $152.6M | $128.2M | ||
| Q4 24 | $266.2M | $174.2M | ||
| Q3 24 | $240.7M | $147.9M | ||
| Q2 24 | $90.4M | $158.6M | ||
| Q1 24 | $178.8M | $147.6M |
自由现金流BLDRVTY
| Q4 25 | $159.4M | $161.8M | ||
| Q3 25 | $216.2M | $120.0M | ||
| Q2 25 | $182.2M | $115.5M | ||
| Q1 25 | $139.2M | $112.2M | ||
| Q4 24 | $253.7M | $149.8M | ||
| Q3 24 | $219.8M | $125.6M | ||
| Q2 24 | $74.3M | $136.6M | ||
| Q1 24 | $158.9M | $129.7M |
自由现金流率BLDRVTY
| Q4 25 | 10.7% | 21.0% | ||
| Q3 25 | 15.5% | 17.2% | ||
| Q2 25 | 14.0% | 16.0% | ||
| Q1 25 | 11.3% | 16.9% | ||
| Q4 24 | 19.3% | 20.5% | ||
| Q3 24 | 16.0% | 18.4% | ||
| Q2 24 | 5.4% | 19.7% | ||
| Q1 24 | 12.4% | 20.0% |
资本支出强度BLDRVTY
| Q4 25 | 1.2% | 2.6% | ||
| Q3 25 | 1.2% | 2.6% | ||
| Q2 25 | 0.9% | 2.6% | ||
| Q1 25 | 1.1% | 2.4% | ||
| Q4 24 | 1.0% | 3.4% | ||
| Q3 24 | 1.5% | 3.3% | ||
| Q2 24 | 1.2% | 3.2% | ||
| Q1 24 | 1.6% | 2.7% |
现金转化率BLDRVTY
| Q4 25 | 1.69× | 1.85× | ||
| Q3 25 | 1.64× | 2.97× | ||
| Q2 25 | 1.28× | 2.49× | ||
| Q1 25 | 1.24× | 3.03× | ||
| Q4 24 | 1.77× | 1.84× | ||
| Q3 24 | 1.42× | 1.57× | ||
| Q2 24 | 0.60× | 2.87× | ||
| Q1 24 | 1.17× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLD
| Distribution Segment | $755.4M | 51% |
| Residential | $557.9M | 38% |
| All Other Products | $91.9M | 6% |
| Glass And Windows | $51.5M | 3% |
| Rain Gutters | $27.1M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
